Your $274 Copay. The $43 Vial.

Introduction

Your insulin copay was calculated against $274. Your insurer paid $43 for the same vial. The gap wasn't an accident, and the company that ran the system put it in writing: a pharmacy benefit manager vice president described the strategy as letting them "drink down the tasty … rebates," a line the FTC quoted directly in its complaint. The agency just got two of the three companies who built that gap to settle. The third is still fighting, on its third delay, while collecting $41 million a month from the Department of Veterans Affairs.

The Three Companies in the Middle

There are two villains in this story, and you need to see how they work together. The first is the set of middlemen: CVS Caremark, Express Scripts, and OptumRx, the three pharmacy benefit managers the FTC named as respondents in Docket No. 9437 on September 20, 2024. Together they administer roughly 80 percent of all U.S. prescriptions. The second is the manufacturers: Eli Lilly, Novo Nordisk, and Sanofi, who set the list prices. The case is about what happened when those two groups started negotiating with each other.

PBMs decide which drugs your insurance plan covers. They build the "formulary," the list of approved medications, and being left off it is close to a death sentence for a drug, because patients on that plan effectively can't get it. So the PBMs used that power as leverage. They told manufacturers: pay us a bigger rebate, and you get better placement on the formulary. Rebates are calculated as a percentage of the list price. To pay a bigger dollar rebate, a manufacturer has to set a higher list price. One Novo Nordisk vice president, quoted in the FTC complaint, said the PBMs were "addicted to rebates."

That's the loop, and it ran for years. The competition flipped upside down. Instead of competing to lower prices, manufacturers competed to raise them, because a higher sticker meant a fatter rebate they could hand the PBM. Humalog's average list price in 1999 was $21. By 2017 it was more than $274, an increase of over 1,200 percent, while the actual cost of making insulin barely moved. Novolog more than doubled, from $122.59 in 2012 to $289.36 in 2018. By 2019, one in four insulin patients couldn't afford the medication they needed to stay alive.

Who Actually Paid the $274

Here's the part that should make anyone with a deductible sit up. The rebate goes to the PBM. But your copay, if you have a deductible or coinsurance, gets calculated against the list price, not the discounted net price the insurer actually pays. A patient with 20 percent coinsurance, for instance, would pay around $55 against that $274 list price — while the insurer's actual net cost for the same vial, after rebates, was $43. The FTC's complaint says it plainly: vulnerable patients "may pay more out-of-pocket for their insulin drugs than the entire net cost of the drug to the commercial payer."

The list price was a fiction nobody actually paid, except the people least able to argue about it. The $231 gap between the $274.70 list price and the $43 net price, confirmed against Eli Lilly's own figures in 2023 reporting, was the room the rebates lived in. And the deductible patient was standing in that room paying full freight.

The Senate Finance Committee documented the mechanics two years before the FTC sued. Its bipartisan Grassley-Wyden investigation.pdf), built on 100,000 pages of internal documents, found Sanofi offering a 2 to 4 percent rebate for preferred placement in 2013, then a 56 percent rebate on the same product by 2018. OptumRx pulled a 68 percent rebate from Lilly on products a smaller PBM was getting at 22 percent. The most damning line came from a Sanofi official's internal note dated July 28, 2017: even after the fees, the company was "still profitable up to an 89 percent rebate." Nearly nine of every ten dollars on the sticker could be handed back, and the manufacturer still made money.

Two Down

Express Scripts folded first. On February 4, 2026, the FTC announced a settlement the agency projected would cut patient out-of-pocket costs by up to $7 billion over ten years. The terms go straight at the mechanism. Express Scripts has to stop preferring high-list-price versions of a drug when an identical low-list-price version exists, and it has to base members' out-of-pocket costs on the net price rather than the inflated list price. The link between a manufacturer's payments and the list price gets broken. And the company has to bring its group purchasing organization, Ascent Health Services, back from Switzerland, where it had been parked, returning more than $750 billion in purchasing activity onto U.S. soil. The offshore GPO was where a chunk of the rebate negotiation lived, conveniently outside easy reach.

CVS Caremark went next. On March 23, 2026, the FTC and CVS filed a joint motion to pull Caremark out of the adjudication to finalize a consent agreement expected to mirror the Express Scripts terms. What the settlements don't include is money. No financial penalties. The orders are behavioral, requiring the companies to change how they operate going forward. A J.P. Morgan analyst told investors the CVS changes were "broadly manageable" and not much bigger than what CVS was already planning, and Cigna executives said the Express Scripts deal mostly cemented reforms the company was already making and wouldn't dent long-term profits. So the companies agree to stop, and they keep everything they collected on the way here.

The Holdout

That leaves OptumRx, owned by UnitedHealth Group, which is separately under a DOJ fraud investigation. It hasn't settled. It's been running out the clock instead. The FTC and OptumRx jointly moved to stay the proceeding on May 19, 2026, telling the Commission they were "close to reaching an agreement." On June 3, 2026, the Commission granted a third stay extension and reset the schedule again. The schedule reset included the oral argument on OptumRx's motion to dismiss — rescheduled again. Both sides say they're close. As of this writing, nothing has been announced. This story is developing. Details may change.

Now hold that next to a different government record. While OptumRx negotiates its way out of an FTC enforcement action, OptumRx Administrative Services holds active pharmacy-benefit contracts with the Department of Veterans Affairs, the kind of work at the center of the FTC case. The monthly delivery orders in USAspending.gov run from roughly $21.7 million to $41.1 million; the December 2024 order alone was $41.1 million. So one arm of the federal government is trying to make OptumRx stop a practice, while another arm pays it tens of millions a month to keep running pharmacy benefits for veterans.

Who Benefits

Follow the money and it lands in one place: the PBMs and their parent conglomerates. The benefit is revenue, and the FTC's own reporting sizes it. The First Interim Report found the Big Three keep "hundreds of millions of dollars in rebates and fees each year." The Second Interim Report found their affiliated pharmacies generated more than $7.3 billion in dispensing revenue above estimated acquisition costs on 51 specialty generic drugs alone between 2017 and 2022, a figure growing at a 42 percent annual clip, plus another $1.4 billion in spread pricing on the same drugs.

The mechanism is what makes it work, and it has a structural protection most industries would envy: secrecy. Every rebate contract between a PBM and a manufacturer is confidential. The Senate Finance Committee needed subpoena power to read them. Until the Consolidated Appropriations Act of 2026, no federal law required PBMs to disclose full drug-level compensation to the employers and unions paying them. That opacity is what let a system overcharging sick people run in plain sight for more than a decade. The offshore GPO in Switzerland was the same instinct in physical form, moving the rebate machinery somewhere harder to see.

The manufacturers benefited too, which is why this is a two-tier story rather than a clean villain. Lilly, Novo, and Sanofi raised prices "in lockstep," per the federal court order consolidating the 444 lawsuits now pending in the New Jersey multidistrict litigation. They got to keep their market share by feeding the rebate machine instead of competing on price. The FTC's competition bureau said it remains "deeply troubled by the role drug manufacturers like Eli Lilly, Novo Nordisk, and Sanofi play in driving up list prices." Nobody in this chain had a reason to stop, because every link got paid.

What the Settlements Actually Settle

The reforms are real, and they matter for the next person filling a prescription. Tying copays to net price instead of list price, killing the high-list-price preference, dragging the offshore GPO back home: those changes attack the exact loop the FTC documented. If they hold, the deductible patient stops paying against a fiction.

But notice the shape of the resolution. The companies that ran a system the FTC says overcharged people who couldn't afford insulin are walking away with no fines, settlements that "largely cemented" changes they were already making, and analyst notes reassuring investors that profits are safe. Two of the three even folded into the agreement an early-access lane to a new federal drug-pricing platform. The enforcement action is functioning less like a punishment and more like a negotiated handoff to a slightly less extractive version of the same business. Manufacturers, meanwhile, have already cut insulin list prices on their own, Humalog down to $66 a vial, still higher than the $43 the insurer was paying. The fiction got smaller without going away.

The Bottom Line

The FTC proved that for years, the sickest people on a plan paid copays against a number their insurer never actually paid, and that three companies engineered the gap on purpose. Two of them settled with no money changing hands. The third is on its third extension while the VA writes it a check every month. The behavioral reforms, if they survive implementation deadlines in 2027 and 2028, will help. What they won't do is answer the question sitting underneath the whole case: if a company can overcharge dying people for a decade and exit with reforms it was "broadly" fine with anyway, what exactly is the deterrent the next time someone finds a wall like this one to build?